NcXHF

NOWAKOWSKI AND CZUCZMAN
15. Aragon-Ching JB, Li H, Gardner ER, et al. Thalidomide analogues as
anticancer drugs. Recent Pat Anticancer Drug Discov. 2007;2:167-174.
16. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory
drug CC-5013 or CC-4047 and rituximab enhance antitumor activity
in a severe combined immunodefıcient mouse lymphoma model.
Clin Cancer Res. 2005;11:5984-5992.
17. Thieblemont C, Delfau-Larue MH, Coiffıer B. Lenalidomide in diffuse
large B-cell lymphoma. Adv Hematol. Epub 2012 Nov 20.
18. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer
cell and monocyte-mediated antibody-dependent cellular cytotoxicity
of rituximab-treated CD20 tumor cells. Clin Cancer Res. 2008;14:
4650-4657.
19. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of
single-agent lenalidomide for relapsed or refractory aggressive B-cell
non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622-1627.
20. Vose JM, Habermann TM, Czuczman MS, et al. Single-agent lenalidomide
is active in patients with relapsed or refractory aggressive non-
Hodgkin lymphoma who received prior stem cell transplantation. Br J
Haematol. 2013;162:639-647.
21. Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte
and lymphocyte prognostic score predicts survival and identifıes highrisk
patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25:1502-
1509.
22. Choi MY, Kipps TJ. Inhibitors of B-cell receptor signaling for patients
with B-cell malignancies. Cancer J. 2012;18:404-410.
23. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton’s tyrosine kinase
(BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the
ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma
(DLBCL): interim results of a multicenter, open-label, phase 2
study. Blood. 2012;120 (suppl; abstr 686).
24. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with
fostamatinib disodium has signifıcant clinical activity in non-Hodgkin
lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-
2585.
25. Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol.
2012;30:3439-3443.
26. Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic
pathways in cancer therapy. Clin Cancer Res. 2009;15:1126-
1132.
27. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large
B-cell lymphoma. J Clin Oncol. 2006;24:995-1007.
28. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective
BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med. 2013;19:202-208.
29. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specifıc BH3 mimetic,
has in vivo effıcacy against aggressive Myc-driven mouse lymphomas
without provoking thrombocytopenia. Blood. 2013;121:2285-2288.
30. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab
for previously untreated diffuse large B-cell lymphoma and mantle cell
lymphoma. J Clin Oncol. 2011;29:690-697.
31. Witzig TE, Tang H, Micallef IN, et al. Multi-institutional phase II study
of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with
relapsed and refractory lymphomas. Blood. 2011;118:4882-4889.
32. Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect
lymphoma B-cells from rituximab-induced apoptosis and targeting integrin
alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance.
Br J Haematol. 2011;155:53-64.
33. Chiappella A, Tucci A, Castellino A, et al. Lenalidomide plus cyclophosphamide,
doxorubicin, vincristine, prednisone and rituximab is
safe and effective in untreated, elderly patients with diffuse large
B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Haematologica. 2013;98:1732-1738.
34. Nowakowski GS, LaPlant B, Habermann TM, et al. Lenalidomide can be
safely combined with R-CHOP (R2CHOP) in the initial chemotherapy
for aggressive B-cell lymphomas: phase I study. Leukemia. 2011;25:
1877-1881.
35. Nowakowski GS, LaPlant BR, Reeder C, et al. Combination of lenalidomide
with R-CHOP (R2CHOP) is well-tolerated and effective as initial
therapy for aggressive B-cell lymphomas - a phase II study. Blood. 2012;
120 (suppl; abstr 689).
36. Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus
R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma:
results of the REAL07 open-label, multicentre, phase 2 trial.
Lancet Oncol. 2014;15:730-737.
37. Nowakowski GS, LaPlant B, Macon WR. Lenalidomide combined with
R-CHOP overcomes negative prognostic impact of non-germinal center
B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma:
a phase II study. J Clin Oncol. 2015;33:251-257.
38. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome
breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.
Science. 1984;226:1097-1099.
39. Younes A, Flinn I, Berdeja J, et al. Combining ibrutinib with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP): updated results from a phase 1b study in treatment-naïve patients
with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL).
Blood. 2013;122 (suppl; abstr 852).
40. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous
transplantation for relapsed large B-cell lymphoma in the rituximab
era. J Clin Oncol. 2010;28:4184-4190.
41. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to
lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in
nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Cancer. 2011;117:5058-5066.
42. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive
B-cell lymphomas: pathogenesis and classifıcation. Blood. 2013;122:
3884-3891.
43. Sewastianik T, Prochorec-Sobieszek M, Chapuy B, et al. MYC deregulation
in lymphoid tumors: Molecular mechanisms, clinical consequences
and therapeutic implications. Biochim Biochim Biophys Acta.
2014;1846;457-467.
44. Karube K, Campo E. MYC Alterations in Diffuse Large B-Cell Lymphomas.
Seminars in Hematology. In press.
45. Pedersen MO, Gang AO, Poulsen TS, et al. MYC translocation partner
gene determines survival of patients with large B-cell lymphoma with
MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;
92:42-48.
46. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple
proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature.
2001;412:341-346.
47. Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number
correlates with increased mRNA levels in diffuse large B-cell lymphoma.
Haematologica. 2010;95:597-603.
48 Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated
with poor prognosis in patients with diffuse large B-cell lymphoma
treated in the era of rituximab. J Clin Oncol. 2010;28:3360-3365.
49. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein
expression and genetic alterations have prognostic impact in patients
with diffuse large B-cell lymphoma treated with immunochemotherapy.
Haematologica. 2013;98:1554-1562.
50. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen
and stem cell transplantation on outcomes in double-hit lymphoma: A
multicenter retrospective analysis. Blood. 2014;124:2354-2361.
51. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit
score is a strong predictor of outcome in patients with diffuse large
e456
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook